Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Infants with congenital heart defects have reduced brain volumes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Oral pre‑treatment with thiocyanate (SCN−) protects against myocardial ischaemia–reperfusion injury in rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Explaining deep neural networks for knowledge discovery in electrocardiogram analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration-response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC50) in different cell types: 7-12 µg/mL), followed by artemether (53-98 µg/mL), A. annua extracts (83-260 µg/mL) and artemisinin (151 to at least 208 µg/mL). The selectivity indices (SI), calculated based on treatment and cell viability assays, were mostly below 10 (range 2 to 54), suggesting a small therapeutic window. Time-of-addition experiments in A549-hACE2 cells revealed that artesunate targeted SARS-CoV-2 at the post-entry level. Peak plasma concentrations of artesunate exceeding EC50 values can be achieved. Clinical studies are required to further evaluate the utility of these compounds as COVID-19 treatment.

OriginalsprogEngelsk
Artikelnummer14571
TidsskriftScientific Reports
Vol/bind11
Udgave nummer1
ISSN2045-2322
DOI
StatusUdgivet - 16 jul. 2021

ID: 66727254